Dublin, April 30, 2026 (GLOBE NEWSWIRE) — The “Antibody Contract Manufacturing Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The antibody contract manufacturing market is experiencing significant growth, with its size expected to rise from $16.79 billion in 2025 to $19.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15%. The expansion is driven by increased biologics development pipelines, outsourcing by biopharmaceutical firms, mammalian cell culture platform expansion, and the rise in clinical trials for antibodies supported by specialized contract manufacturing infrastructure.
Future projections indicate that the market will attain $34.72 billion by 2030, growing at a CAGR of 15.8%. The demand surge for commercial-scale antibody production, next-generation biologics investments, and a focus on cost-efficient manufacturing underpin this trend. Other driving factors include personalized medicine pipeline expansion and regulatory approvals for antibody therapies. Key trends include the adoption of single-use bioprocessing systems, demand for bispecific antibodies, flexible manufacturing models, and enhanced regulatory compliance and quality control emphasis.
Clinical trial activity is playing a pivotal role in market expansion. A notable increase in trials related to antibody-based therapeutics augments demand for high-quality antibodies, ensuring timely supplies. ClinicalTrials.gov reported an increase in registered trials from 399,499 in 2022 to 437,533 in 2023, emphasizing the growing research scale globally.
Leading industry players are focusing on innovations like single-use technologies to mitigate cross-contamination risks and reduce costs. For instance, Merck & Co.’s release of the Mobius ADC Reactor in 2024 marked a significant improvement in manufacturing efficiency for antibody-drug conjugates. Meanwhile, Agilent Technologies’ acquisition of BIOVECTRA aims to boost its contract development and manufacturing capabilities and expand its biologics portfolio.
Prominent companies operating in this space include Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, and others. Geographically, North America was the largest market in 2025, while Asia-Pacific is forecasted to grow the fastest. Regions such as Asia-Pacific, South East Asia, and various global countries are key players in the market landscape.
Tariff impacts are causing increased production costs for bioreactors and related equipment, but also spur localized manufacturing investments and regional supplier growth. Despite these challenges, the antibody contract manufacturing market remains robust, providing essential services for cell line development, process optimization, and clinical trial material production.
Antibody contract manufacturing, crucial for producing monoclonal and polyclonal antibodies, remains vital for therapeutic and diagnostic applications. The market’s value includes both service-related and direct end-user sales, excluding secondary market revenues. The ongoing growth highlights the importance of this sector in the biopharmaceutical and biotechnology industries.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $19.32 Billion |
| Forecasted Market Value (USD) by 2030 | $34.72 Billion |
| Compound Annual Growth Rate | 15.8% |
| Regions Covered | Global |
Major Trends
- Expansion of Large-Scale Antibody Manufacturing Capacity
- Rising Adoption of Single-Use Bioprocessing Systems
- Growing Demand for Bispecific Antibodies and Adcs
- Increased Focus on Flexible and Scalable Manufacturing Models
- Enhanced Emphasis on Regulatory Compliance and Quality Control
Market Scope:
- Product Segmentation: Monoclonal Antibodies; Polyclonal Antibodies; Other Products.
- Source Segmentation: Mammalian; Microbial.
- Scale of Operation: Preclinical, Clinical, Commercial.
- End-User: Biopharmaceutical Companies; Research Laboratories.
Companies Featured
- Lonza Group AG
- Catalent Inc
- Samsung Biologics Co Ltd
- Wuxi Biologics Cayman Inc
- Thermo Fisher Scientific Inc
- Boehringer Ingelheim BioXcellence
- AGC Biologics
- FUJIFILM Diosynth Biotechnologies
- AbbVie Inc
- Charles River Laboratories International Inc
- mAbxience
- KBI Biopharma Inc
- Abzena Ltd
- Just-Evotec Biologics
- Northway Biotech
- Cerbios-Pharma
- Scorpius BioManufacturing
- Lotte Biologics
- Rentschler Biopharma SE
- Cytiva (Life Sciences CDMO)
- Xcellon Biologics
- Celonic AG
- Syngene International Ltd
For more information about this report visit https://www.researchandmarkets.com/r/das8m4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Antibody Contract Manufacturing Market
